Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Genomics
• Cancer Research

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer mortality.
• HPV-negative HNSCC is particularly aggressive, with poor prognosis and limited response to radiotherapy.
• There is a critical need for improved prognostic tools and treatment strategies for these patients.

Purpose of the Study:

• To assess the prognostic capability of gene expression signatures in predicting survival for HPV-negative HNSCC patients undergoing radiotherapy.
• To compare the accuracy of these signatures against the established TNM staging system.

Main Methods:

• An observational cohort study analyzed gene expression data from 783 HPV-negative HNSCC patients (stage III-IVa/b) treated with curative radiotherapy.
• Primary outcome was overall survival (OS); secondary outcomes included disease-free survival (DFS), distant metastasis-free survival (DMFS), and loco-regional recurrence-free survival (LRRFS).
• Prognostic performance was evaluated using receiver operating characteristic (ROC) curves and Cox models.

Main Results:

• The 172-gene signature (172GS) demonstrated the highest prognostic accuracy.
• 172GS outperformed the TNM staging system in predicting OS, DFS, DMFS, and LRRFS.
• Multivariable analysis confirmed the independent prognostic value of the 172GS.

Conclusions:

• The 172GS gene signature offers superior prognostic information over TNM staging for HPV-negative HNSCC.
• This signature holds potential for enhanced risk stratification and personalized treatment planning.
• Future research should incorporate tumor biology and gene signatures for optimal patient selection in clinical trials.